Amgen (AMGN) Shares are Down -0.95%

On a relative basis, the stock has outperformed the S&P 500 by 0.18% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The 4-week change in the price of the stock is -0.03% and the stock has fallen -0.95% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.29% and the fifty day Moving Average is 5.46%. Amgen Inc. is up 10.35% in the last three month period. Year-to-Date the stock performance stands at 8%.

Amgen (AMGN) stock is expected to deviate a maximum of $16.14 from the average target price of $186.27 for the short term period. 11 Street Experts have initiated coverage on the stock with the most promising target being $209 and the most muted being $157.


Amgen (NASDAQ:AMGN): stock turned positive on Friday. Though the stock opened at $170.8, the bulls momentum made the stock top out at $172.99 level for the day. The stock recorded a low of $169.765 and closed the trading day at $171.97, in the green by 1.02%. The total traded volume for the day was 2,925,290. The stock had closed at $170.23 in the previous days trading.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *